nerd
Senior Member
- Messages
- 863
Highlights
Nicolas Panayotis, Philip A. Freund, Letizia Marvaldi, Tali Shalit, Alexander Brandis, Tevie Mehlman, Michael M. Tsoory, Mike Fainzilber,
β-sitosterol reduces anxiety and synergizes with established anxiolytic drugs in mice, Cell Reports Medicine, Volume 2, Issue 5, 2021, 100281, ISSN 2666-3791, doi: 10.1016/j.xcrm.2021.100281
- In silico screen identifies β-sitosterol as a candidate anxiolytic drug
- β-sitosterol is anxiolytic in both naive and chronically stressed mice
- β-sitosterol alters the expression of immediate early genes
- Sub-efficacious doses of β-sitosterol and fluoxetine synergize when combined
Anxiety and stress-related conditions represent a significant health burden in modern society. Unfortunately, most anxiolytic drugs are prone to side effects, limiting their long-term usage. Here, we employ a bioinformatics screen to identify drugs for repurposing as anxiolytics. Comparison of drug-induced gene-expression profiles with the hippocampal transcriptome of an importin α5 mutant mouse model with reduced anxiety identifies the hypocholesterolemic agent β-sitosterol as a promising candidate. β-sitosterol activity is validated by both intraperitoneal and oral application in mice, revealing it as the only clear anxiolytic from five closely related phytosterols. β-sitosterol injection reduces the effects of restraint stress, contextual fear memory, and c-Fos activation in the prefrontal cortex and dentate gyrus. Moreover, synergistic anxiolysis is observed when combining sub-efficacious doses of β-sitosterol with the SSRI fluoxetine. These preclinical findings support further development of β-sitosterol, either as a standalone anxiolytic or in combination with low-dose SSRIs.
Nicolas Panayotis, Philip A. Freund, Letizia Marvaldi, Tali Shalit, Alexander Brandis, Tevie Mehlman, Michael M. Tsoory, Mike Fainzilber,
β-sitosterol reduces anxiety and synergizes with established anxiolytic drugs in mice, Cell Reports Medicine, Volume 2, Issue 5, 2021, 100281, ISSN 2666-3791, doi: 10.1016/j.xcrm.2021.100281